Class action settlement agreement

Published on July 22, 2025

Johnson & Associates v. MegaCorp - Class Action Settlement

Achieved favorable $45M settlement in nationwide class action against pharmaceutical company for misleading drug marketing.

Client

Johnson & Associates (Class Counsel)

Practice

litigation

Jurisdiction

U.S. District Court (Southern District of New York)

Value

$45M settlement

Result

$45 million settlement approved by court, benefiting 50,000+ class members.

Category

Class Action

Meet the legal team

Attorneys Involved

Our attorneys bring deep expertise and dedication to every case. Learn more about the professionals who guided this matter to a successful resolution, each contributing specialized skills and strategic insight to deliver results for our client.

Michael Rodriguez portrait

Michael Rodriguez

Litigation Partner

Chicago Office

Commercial LitigationClass Action DefenseProduct Liability
View Profile
Emily Johnson portrait

Emily Johnson

Family Law Associate

Washington, DC Office

Divorce and SeparationChild Custody and SupportDomestic Partnerships
View Profile

Client Testimonial

"This settlement provides real relief to thousands of patients who were harmed by misleading drug claims."

— Lead Plaintiff

Case Overview

Johnson & Associates filed a nationwide class action lawsuit against MegaCorp Pharmaceuticals, alleging that the company engaged in deceptive marketing practices for their blockbuster diabetes medication. The complaint claimed that MegaCorp overstated the drug’s effectiveness while downplaying serious side effects.

Allegations

  • False advertising regarding clinical trial results
  • Misrepresentation of drug safety profile
  • Failure to disclose known side effects
  • Targeted marketing to vulnerable patient populations

Litigation Process

  • Class Certification: Successfully certified a class of 50,000+ patients who purchased the medication
  • Discovery: Extensive document production and deposition testimony revealed internal company communications acknowledging the misleading claims
  • Mediation: Multiple mediation sessions led to a comprehensive settlement agreement

Settlement Terms

The $45 million settlement provides:

  • Cash payments to class members based on usage and harm
  • Medical monitoring program for at-risk patients
  • Corrective advertising campaign
  • Establishment of patient education fund

Court Approval

After thorough review, the district court approved the settlement as fair, reasonable, and adequate. The settlement has been praised by consumer advocacy groups for providing meaningful relief to affected patients.

Broader Impact

This case contributes to ongoing efforts to hold pharmaceutical companies accountable for truthful marketing and patient safety.